---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-051280"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T03:04:26.086620+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn discontinues FHD-286 in AML; prioritizes pipeline and Lilly collaboration

## Summary
- FHD-286 + decitabine showed objective responses in Phase 1 but efficacy threshold not met for continued standalone development.
- Company evaluating partnerships/ISTs for FHD-286; independent development halted.
- Priorities: proprietary CBP, EP300, ARID1B programs and Lilly collaboration including SMARCA2 inhibitor FHD-909.
- Cash of $267.4M as of Sept 30, 2024; runway into 2027.

## SEC filing metadata
- accession: 0001628280-24-051280
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024051280/0001628280-24-051280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024051280/fhtx-20241216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-051280
- JSON: https://secwatch.observer/filing/0001628280-24-051280.json
- Plain text: https://secwatch.observer/filing/0001628280-24-051280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.